Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects

Conclusion:
The combined results of these trials have led to the FDA approval of CCh for the treatment of PD. However, the long-term effects and results need further investigation, with large follow-up series. Considering these results, future perspectives will probably result in the use of a combined or sequential therapy including CCh.

Source: Therapeutic Advances in Urology - August 19, 2014 Category: Urology & Nephrology Authors: Egui Rojo, M. A., Moncada Iribarren, I., Carballido Rodriguez, J., Martinez-Salamanca, J. I. Tags: Reviews Source Type: research